Coalition For Epidemic Preparedness Innovations (cepi) - Vaccines

Relevant Publications

A prospective cohort study of SARS-CoV-2 infection-induced seroconversion and disease incidence in German healthcare workers before and during the rollout of COVID-19 vaccines.

Issue Release: 2024

Estimating the population effectiveness of interventions against COVID-19 in France: A modelling study.

Issue Release: 2024

A Strategic Guide to Improve and De-risk Vaccine Development: CEPI\'s CMC Framework.

Issue Release: 2024

Quantitative assay to analyze neutralization and inhibition of authentic Middle East respiratory syndrome coronavirus.

Issue Release: 2024

Chronic chikungunya disease (CCD): clinical insights, immunopathogenesis, and therapeutic perspectives.

Issue Release: 2024

Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis.

Issue Release: 2024

Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data.

Issue Release: 2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.

Issue Release: 2024

Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents.

Issue Release: 2023

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Issue Release: 2023

Anosmia: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Issue Release: 2023

Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.

Issue Release: 2023

The Coalition for Epidemic Preparedness Innovations (CEPI) and the Partnerships of Equitable Vaccine Access.

Issue Release: 2023

Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential.

Issue Release: 2022

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.

Issue Release: 2022

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.

Issue Release: 2022

Thrombosis and thromboembolism: Brighton collaboration case definition and guidelines for data collection, analysis, and presentation of immunization safety data.

Issue Release: 2022

Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.

Issue Release: 2022

Opportunities for Refinement of Non-Human Primate Vaccine Studies.

Issue Release: 2021

Supply and delivery of vaccines for global health.

Issue Release: 2021

Where Can I Find More Information?

Why Continue Vaccination?

Who Should Get Inactivated Vaccines?

What is Guillain-Barré Syndrome?

Are There Special Considerations for Specific Populations?

How Do Pathogens Evolve and Affect Vaccine Efficacy?

How is NGS Relevant to Vaccine Development?

Can Patients on Immunosuppressive Therapy Receive Vaccines?

What Ethical Considerations are Involved?

How Does the RTS,S/AS01 Vaccine Work?

Coalition For Epidemic Preparedness Innovations (cepi) - Vaccines

Relevant Publications

Partnered Content Networks

Relevant Topics